Evaluation of the Safety and Tolerability of Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy in the Second (Contralateral) Eye of Participants With Bilateral Neovascular Age-related Macular Degeneration.

The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of age) who have been diagnosed with bilateral neovascular (wet) age related macular degeneration (nAMD). The study will enroll adults with nAMD in both eyes, including participants who previously received Ixo-vec treatment in one (initial) eye and/or participants who will receive Ixo-vec treatment for the first time. This study focuses on how the treatment works when both eyes are treated at different times and how effective and long-lasting Ixo-vec treatment is in the second (contralateral) eye.
Participants will receive a single administration of Ixo-vec in the contralateral eye and will be followed for approximately 5 years to evaluate safety, efficacy and durability of contralateral treatment. Secondary objectives include assessments that will evaluate clinical activity, including visual and anatomic outcomes, as well as the need for supplemental anti-VEGF therapy.
The study is intended to provide additional information on the safety, tolerability, and use of Ixo-vec in bilateral treatment.

开始日期2026-06-02

申办/合作机构

Adverum Biotechnologies, Inc.

NCT07482176

/ Recruiting临床3期

A Multi-center, Randomized, Double-masked, Active-comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to intravitreal aflibercept (active comparator). The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured as an average at Weeks 52 and 56.
Safety, tolerability, and efficacy will be evaluated throughout the study.

开始日期2026-03-16

申办/合作机构

Adverum Biotechnologies, Inc.

NCT06856577

/ Active, not recruiting临床3期

A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS)

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56.
Safety, tolerability, and efficacy will be evaluated throughout the study.

开始日期2025-02-28

申办/合作机构

Adverum Biotechnologies, Inc.

100 项与 Ixoberogene soroparvovec 相关的临床结果

登录后查看更多信息

100 项与 Ixoberogene soroparvovec 相关的转化医学

登录后查看更多信息

100 项与 Ixoberogene soroparvovec 相关的专利（医药）

登录后查看更多信息

项与 Ixoberogene soroparvovec 相关的文献（医药）

2026-05-01·CURRENT OPINION IN OPHTHALMOLOGY

Emerging solutions for neovascular age-related macular degeneration

Review

作者: Wubben, Thomas J ; Franco, Jovany J

Purpose of review:

To summarize emerging therapeutic strategies for neovascular (wet) age-related macular degeneration (nAMD), with emphasis on recent translational and clinical developments.

Recent findings:

The nAMD treatment landscape is rapidly evolving. Gene therapies (e.g. ABBV-RGX-314, ADVM-022, and 4D-150) have demonstrated sustained intraocular anti-VEGF expression with reduced injection burden in phase 2 and 3 programs, validating the ‘biofactory’ concept. Tyrosine kinase inhibitors delivered via intravitreal or suprachoroidal implants (e.g. EYP-1901, OTX-TKI, and CLS-AX) show potential for twice-yearly or less frequent dosing. Moreover, emerging therapeutic approaches increasingly target non-VEGF pathogenic pathways, reflecting a shift toward mechanistically diverse vascular stabilization and neuroprotection strategies. These include multitargeted biologics that couple anti-angiogenic and anti-inflammatory effects (e.g. KSI-501, IBI-302, and AG-73305), as well as agents modulating FGF2 signaling, Wnt activation, complement regulation, and cellular metabolism.

Summary:

Therapeutic innovation in nAMD is transitioning from incremental refinements in intravitreal anti-VEGF delivery to strategies aimed at extending durability or targeting alternative contributory pathways. Long-term safety, efficacy, and durability will determine which of these candidates redefine standard care.

2025-08-04·MOLECULAR PHARMACEUTICS

A Semimechanistic Ocular Pharmacokinetic Model for ADVM-022 Gene Therapy Describing the Dose-Exposure Relationship in Monkeys and the Scaling to Human

Article

作者: Hugi, Florian ; Renaud, Lionel ; Vollmer, Jannik ; Machacek, Matthias

Gene therapies are emerging as a new treatment modality. Due to their novelty, general pharmacological properties have yet to be established. For example, the translation from animal models to humans for first-in-human dose selection and the dose-exposure relationship remain poorly characterized. A mechanistic and quantitative framework would improve preclinical program design, enable more robust first-in-human dose predictions, and support more rigorous dose adjustments during clinical development. This study establishes a semimechanistic mathematical model for aflibercept expression and pharmacokinetics (PK) following intravitreal (IVT) ADVM-022 administration in monkeys and humans, drawing on the preclinical and clinical data presently available. ADVM-022 is an AAV2.7m8-based viral vector that delivers the gene encoding aflibercept, an antivascular endothelial growth factor (VEGF) fusion protein. It was developed as a gene therapy for treating wet age-related macular degeneration (wAMD) and is administered through a single IVT injection. The proposed model incorporates established ocular PK for intravitreally administered proteins, along with an expression component that links AAV dose to aflibercept production. Based on pooled PK data from monkey studies, the model suggests that transduction occurs not only in the retina but also in other ocular tissues bordering the vitreous, contributing to the observed intraocular aflibercept levels. Increasing doses within the lower range of preclinical studies (3 × 10¹⁰-2 × 10¹³ vg/eye) lead to increased transduction and expression, plateauing at upper limits of approximately 12.7 μg/day·cm³ for the retina, and 0.785 μg/day for extra-retinal tissues at higher doses. Assuming similar transduction efficiency between humans and monkeys, with adjustments for anatomical differences, the model provided predictions of ocular aflibercept concentrations that aligned with observations from the two dose groups in the phase 1 OPTIC clinical trial, supporting the utility of this approach.

2025-07-01·International ophthalmology clinics

Gene Therapy in Age-related Macular Degeneration

Review

作者: Zhou, Henry W ; Kim, Leo A

Recent advances in gene therapy and salient features of the current AMD therapeutic landscape have led to increased interest in applying gene therapy approaches to AMD. This review will discuss approaches to drug administration, viral and non-viral delivery vectors, and current trials in gene therapy for both wet and dry AMD. Drug administration routes include subretinal, intravitreal, and suprachoroidal approaches. Viral vectors include adenoviral, lentiviral, and adeno-associated viral (AAV) vectors. Non-viral vectors include lipid nanoparticle (LNP) and polymer-based vectors. Current trials in wet AMD include ADVM-022 and RGX-314. Current trials in dry AMD include GT-005 and JNJ-1887.

179

项与 Ixoberogene soroparvovec 相关的新闻（医药）

2026-05-20

·世易眼科汇

眼科领域基因治疗的转变

抗VEGF时代后的未满足需求过去10年间，抗VEGF生物制剂的玻璃体腔注射显著改善了多种视网膜疾病的治疗方式，尽管其仍存在一定局限性。尽管大量研究已证实抗VEGF药物在治疗nAMD、DR及DME中的疗效，但最大获益往往出现在高度受控、规律频繁注射抗VEGF药物的临床试验环境中，而真实世界常规临床实践中的注射频率通常更低。临床实践中较长的注射间隔可能导致疾病活动控制不足，并随着时间推移增加视力丧失风险。患者往往会发现频繁往返医院接受注射极具挑战性。影响抗VEGF注射依从性的障碍包括后勤问题、社会经济因素、合并疾病以及对注射的恐惧。未能遵循推荐给药方案，可能由于药物浓度波动及视网膜厚度反复变化，而导致长期视力结局欠佳，这种情况尤其容易发生于非计划性的长时间注射间隔期间。尽管新获批药物可在一定程度上延长给药间隔，但其持续作用时间仍可能有限，而视网膜专科医生在2025年仍将“更长效疗法”视为nAMD治疗中最大的未满足需求。基因治疗理念的兴起基因治疗有望通过减少甚至消除反复玻璃体腔注射这一沉重循环，解决上述问题。抗VEGF药物的抗血管生成特性结合更持久的基础治疗效应，有潜力改善长期视力结局，并符合临床对于安全、有效、持久且实用疗法的期待。事实上，在2025年ASRS偏好与趋势调查中，基因治疗被列为“最令人兴奋的治疗方式”。值得注意的是，当新生血管性年龄相关性黄斑变性（nAMD）于1885年首次被正式描述为“老年性黄斑疾病”时，人们根本无法想象视网膜细胞能够自行产生药物。而到了2025年，基因治疗不仅已被广泛理解，更成为临床现实，并有望很快成为视网膜专科医生治疗武器库中的一种新选择。从遗传性疾病到常见视网膜疾病基因治疗于2017年首次进入眼科领域，当时voretigene neparvovec-rzyl获批用于治疗Leber先天性黑矇这一罕见遗传性视网膜疾病。这一里程碑式批准为该理念扩展至常见非遗传性视网膜疾病，如nAMD、糖尿病视网膜病变（DR）及糖尿病黄斑水肿（DME）打开了大门。用于视网膜疾病的基因治疗通过病毒载体将“制造特定蛋白”的指令转导至视网膜细胞。转导后，细胞被编程表达因基因突变而缺失或功能异常的正常蛋白（如RPE65），或产生在正常情况下并不内源性表达、但对nAMD、DR及DME等获得性疾病具有治疗价值的蛋白（如阿柏西普）。当前临床开发格局目前，多项采用专有载体的临床研究项目已显示出功能学及解剖学获益，同时减少了频繁抗VEGF注射需求。在遗传性与获得性视网膜疾病中均证实临床价值后，多项基因治疗项目现已积累数年临床数据，以支持其疗效、耐受性及持久性。目前，共有3种研究性基因治疗候选药物正在开展nAMD临床试验：4D-150（4FRONT-1，3期；4FRONT-2，3期）、ADVM-022（ARTEMIS，3期）以及ABBV-RGX-314（ATMOSPHERE，3期；ASCENT，3期；AAVIATE，2期）。4D-150与ADVM-022采用玻璃体腔注射，而ABBV-RGX-314则通过视网膜下（3期）或脉络膜上腔（2期）给药。这些临床项目均利用改良AAV载体，将编码阿柏西普（4D-150与ADVM-022）或雷珠单抗（ABBV-RGX-314）的基因导入视网膜细胞。除阿柏西普外，4D-150递送的遗传载荷还包含第二个转基因，用于编码针对VEGF-C的抑制性RNA序列，在临床前模型中可增强阿柏西普表达。 4D-150、ADVM-022及ABBV-RGX-314均是医生与研究申办方数十年持续合作的成果，其共同目标是优化nAMD、DR及DME等视网膜疾病患者的长期视力结局。患者选择与临床应用思考部分视网膜专科医生可能倾向于仅将基因治疗用于治疗负担较高患者，而另一些医生则可能基于患者个体因素考虑更早干预。4D-150与ADVM-022的3期研究同时纳入初治及既往接受治疗患者，而ABBV-RGX-314的3期项目则仅纳入既往接受过抗VEGF治疗的患者。未来这些研究的进一步分析结果，将有助于明确哪些患者群体获益最大，以及何时进行基因治疗最为合适，从而指导患者筛选。安全性与免疫相关问题对于基因治疗等研究性疗法而言，安全性无疑是最受关注的问题之一。腺相关病毒（AAV）基因治疗项目的潜在担忧包括炎症与免疫原性风险、潜在脱靶效应，以及转导后无法关闭蛋白表达的问题。相较其他器官，视网膜具备多项天然优势，使其成为基因治疗最理想的靶器官之一。视网膜由稳定、非分裂性细胞群构成，而相对较小的组织体积（约65 mm³）使局部给药成为可能。血视网膜屏障则有助于减少眼内注射药物的全身暴露，从理论上降低炎症相关不良事件及全身脱靶效应风险。由于研究设计、衣壳特性、抗VEGF基因产物以及给药途径（即视网膜下、脉络膜上腔及玻璃体腔）不同，目前尚无法直接比较不同项目或不同载体之间的结果。不同临床项目的给药剂量亦存在差异，而较低剂量理论上更不容易诱发免疫反应，因此可能影响整体安全性特征。为降低眼内炎症风险，2期研究通常采用预防性类固醇方案。正在进行的玻璃体腔基因治疗3期研究均采用至少20周的预防性局部糖皮质激素减量方案。而采用视网膜下给药的3期研究则未采用预防性类固醇方案，这可能与手术环境下病毒衣壳局限于较小、明确区域有关。目前，1/2期nAMD基因治疗试验已获得最长达4年的随访数据，总体耐受性良好，并显示持续且长期的治疗效果。未来展望当前3期研究项目在实施基因治疗前均会评估患者对抗VEGF治疗的反应，目的是将该疗法用于最可能获益的患者。鉴于已有数据支持在nAMD及DME等疾病中维持持续治疗的重要性，细胞转导的永久性或许应被视为实现长期疾病控制的有利特征，而非阻碍因素。如果获得批准，这些基因治疗的临床应用将需要综合考虑整体安全性与疗效数据，同时兼顾实际使用便利性及个体患者需求。目前，全球已有数百家研究中心积极参与这些3期项目的推进。表格中列出了各3期研究的关键数据读出时间线，也预示着向监管机构递交潜在上市申请这一激动人心的阶段即将开启。 Reference 1. https://europe.ophthalmologytimes.com/view/the-gene-therapy-shift

2026-05-20

·BioSpace

Lilly and Engage Bio tie the knot with $202M acquisition

iStock, Smashing Stocks Eli Lilly joins hands with Engage Bio, acquiring the DNA delivery platform developer in hopes of bolstering its genetic medicines portfolio. Buoyed by its weight-loss windfall, Eli Lilly is continuing its dealmaking streak by buying a preclinical biotech developing a nonviral DNA delivery platform. The Big Pharma is acquiring Engage Bio for up to $202 million in cash, which includes upfront and milestone payments, according to a Wednesday release . At the heart of the deal is Engage’s Tethosome platform, tech that is designed to address current limitations in DNA delivery by improving potency, tolerability and redosability. Engage’s platform combines engineered DNA payloads with lipid nanoparticle delivery and the biotech’s own mRNA tech aimed at enhancing localization and boosting expression. The San Carlos, California–based biotech’s platform is supposed to help create a new class of nonviral DNA medicines, though the company has not publicly disclosed any programs. Founded in 2021 by CEO Will Olsen —formerly of Rejuvenation Technologies and Luminist Labs—Engage has previously raised “modest seed funding,” Olsen said in a prepared statement. The biotech hasn’t shared specifics on past financings but has received support from SciFounders, Pioneer Fund, Cal Innovation Fund, Y Combinator, the Gates Foundation and the National Institutes of Health, according to the release. While the newly joined companies didn’t reveal what indications they would be going after, Engage has also received past financial backing from the Cystic Fibrosis Foundation. Deals Lilly can’t stop the dealing, with nearly $21B spent on M&A this year—so far With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains. April 29, 2026 · 2 min read · Annalee Armstrong Read more Lilly doesn’t currently market any gene therapies, but the pharma has been building out its genetic medicines pipeline. Late-stage programs include lepodisiran, an siRNA therapy made to reduce Lp(a) levels among individuals with elevated heart disease risk, and ixoberogene soroparvovec, a one-time gene therapy for wet age-related macular degeneration. The latter was secured last year in the up to $262 million buyout of Adverum Biotechnologies. The pharma also touts the adeno‑associated virus (AAV) vector-based gene therapy AK-OTOF, which is being tested for its ability to treat inherited hearing loss. Last month, Lilly offered up to $2.25 billion to work with AI-focused Profluent Bio on developing new DNA editing tools and more precise treatments for genetic conditions, and another $3.25 billion in cash for in vivo CAR T–focused Kelonia—the third in vivo transaction for Lilly in the past year. As of the end of April, Lilly had spent nearly $21 billion on M&A activity, with six biotech buyouts in the books for 2026.

并购基因疗法信使RNA

2026-05-18

·同写意

芳拓生物卡位千亿眼科基因治疗赛道

100 项与 Ixoberogene soroparvovec 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
湿性年龄相关性黄斑变性	临床3期	美国	Adverum Biotechnologies, Inc.	2025-02-28
糖尿病性黄斑水肿	临床2期	美国	Adverum Biotechnologies, Inc.	2020-05-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04645212 (OPTIC, EURETINA2025)	临床2期	湿性年龄相关性黄斑变性	90	Ixoberogene soroparvovec 2x1011 vg/eye	餘鹽觸製齋製艱襯蓋鹽(鏇顧齋窪製艱顧廠衊網) = most common Ixo-vec-related AEs were dose-dependent, anterior inflammation responsive to local corticosteroid and anterior pigmentary changes with no impact on vision 顧廠選衊襯窪製醖積鏇 (觸網獵觸淵遞鑰遞鑰淵 )	积极	2025-09-04
				Ixoberogene soroparvovec 6x1010 vg/eye
NCT04418427 (INFINITY, CTgov)	临床2期	糖尿病性黄斑水肿	36	6E11+ADVM-022+Aflibercept (ADVM-022 6E11 vg/Eye)	艱積願鏇淵壓網範網淵(餘觸艱構齋觸網築蓋窪) = 築鑰積觸衊獵齋襯製觸構選鹹艱獵遞餘蓋憲窪 (膚繭餘構醖製繭壓構獵, 醖鏇鏇餘鹹廠襯膚艱鹹 ~ 築襯衊築鬱鹹遞艱糧夢) 更多	-	2025-07-10
				ADVM-022+Aflibercept (ADVM-022 2E11 vg/Eye)	艱積願鏇淵壓網範網淵(餘觸艱構齋觸網築蓋窪) = 糧構鬱廠觸衊淵構遞夢構選鹹艱獵遞餘蓋憲窪 (膚繭餘構醖製繭壓構獵, 醖夢顧廠艱鹽觸遞積壓 ~ 簾獵製範鏇鬱鑰構顧糧) 更多
NCT04645212 (OPTIC, ARVO2025)	临床1/2期	湿性年龄相关性黄斑变性	30	Ixoberogene soroparvovec (Ixo-vec) 6x10^11 (6E11) vg/eye	衊簾範壓衊壓構夢積鹹(獵壓衊範淵製範製鹹觸) = For both groups, through 4 years, there were no cases of retinitis, vasculitis, choroiditis, vascular occlusive events, or hypotony. Ixo-vec demonstrated a reliable long-term benefit; 90% of participants who were injection free through year 2 remained injection free through year 4. 願蓋鹽壓餘膚鬱顧網築 (蓋遞鬱繭選廠膚齋餘鬱 )	积极	2025-05-04
				Ixoberogene soroparvovec (Ixo-vec) 2x10^11 (2E11) vg/eye
NCT05536973 (LUNA, ARVO2025)	临床2期	湿性年龄相关性黄斑变性	60	Ixoberogene Soroparvovec 6x10^10 vg/eye	憲願膚廠衊鬱構積願繭(淵廠製淵襯淵構廠襯醖) = 築願築構鬱憲範鑰襯鹹繭製廠鏇鑰憲糧繭築構 (襯壓觸顧觸鹹窪壓衊觸 ) 更多	积极	2025-05-04
				Ixoberogene Soroparvovec 2x10^11 vg/eye	憲願膚廠衊鬱構積願繭(淵廠製淵襯淵構廠襯醖) = 網衊壓製餘窪餘夢艱艱繭製廠鏇鑰憲糧繭築構 (襯壓觸顧觸鹹窪壓衊觸 ) 更多
NCT03748784 (OPTIC, GlobeNewswire) 人工标引	临床1期	湿性年龄相关性黄斑变性	30	Ixo-vec	範憲簾網鏇願構繭積簾(願鬱餘窪鹹鬱壓醖願壓) = 蓋製廠觸憲膚繭網鹽製膚艱鑰觸繭獵願鏇鑰觸 (遞壓餘齋繭範構糧壓壓 ) 更多	积极	2024-11-18
NCT05536973 (LUNA, GlobeNewswire) 人工标引	临床2期	湿性年龄相关性黄斑变性	60	6E10 Ixo-vec	廠糧鏇鹽選壓衊鹽醖窪(繭選網廠襯衊膚廠糧網) = 夢鏇艱獵夢鏇構簾糧窪淵觸選齋構範顧遞繭鏇 (網顧齋範蓋壓顧築鹽窪, -4.8 ~ 0.7) 更多	积极	2024-11-18
				2E11 Ixo-vec	廠糧鏇鹽選壓衊鹽醖窪(繭選網廠襯衊膚廠糧網) = 願夢醖醖鬱鹽餘壓餘夢淵觸選齋構範顧遞繭鏇 (網顧齋範蓋壓顧築鹽窪, -4.6 ~ 0.9) 更多
NCT05536973 (LUNA, EURETINA2024)	临床2期	湿性年龄相关性黄斑变性 anti-VEGF therapy	60	Ixoberogene Soroparvovec (Ixo-vec) (Ixo-vec 6x10^10 vg/eye)	醖鹹製憲糧鑰齋蓋網膚(憲築製餘鬱鏇簾簾鑰夢) = 鑰構選範鬱鹽齋遞顧繭繭鹹簾餘選網淵襯齋願 (齋糧鏇製襯壓遞鹹製憲 ) 更多	积极	2024-09-19
				Ixo-vecgene Soroparvovec (Ixo-vec) (Ixo-vec 2x10^11 vg/eye)	醖鹹製憲糧鑰齋蓋網膚(憲築製餘鬱鏇簾簾鑰夢) = 願願夢糧鑰壓糧衊膚網繭鹹簾餘選網淵襯齋願 (齋糧鏇製襯壓遞鹹製憲 ) 更多
NCT05536973 (GlobeNewswire) 人工标引	临床2期	湿性年龄相关性黄斑变性	60	Ixo-vec 6E10	遞憲鑰積衊糧構廠襯網(衊鹹餘齋築鹹鬱壓獵襯) = 構齋餘衊顧糧範觸艱構獵範範範構鏇鑰願蓋膚 (淵簾艱鬱鑰憲築願鑰簾 ) 更多	积极	2024-07-17
				Ixo-vec 2E11	遞憲鑰積衊糧構廠襯網(衊鹹餘齋築鹹鬱壓獵襯) = 衊觸範獵簾觸繭積鑰積獵範範範構鏇鑰願蓋膚 (淵簾艱鬱鑰憲築願鑰簾 ) 更多
NCT05536973 (LUNA, Biospace) 人工标引	临床2期	湿性年龄相关性黄斑变性	60	Ixo-vec 2E11 vg/eye	醖廠製糧鏇憲淵糧獵壓(網糧齋夢鏇鹽願選醖壓) = 簾繭獵齋壓憲艱廠觸膚鹹築鹽顧齋網餘齋構觸 (膚鏇簾鬱鹽淵網夢繭鑰 ) 更多	积极	2024-02-08
				Ixo-vec 6E10 vg/eye	醖廠製糧鏇憲淵糧獵壓(網糧齋夢鏇鹽願選醖壓) = 壓衊觸繭艱蓋積遞齋鏇鹹築鹽顧齋網餘齋構觸 (膚鏇簾鬱鹽淵網夢繭鑰 ) 更多
OPTIC extension (GlobeNewswire) 人工标引	临床2期	湿性年龄相关性黄斑变性	-	ADVM-022 2E11	鹽衊蓋糧夢廠鹹築壓獵(鏇衊鹹憲壓糧齋糧鏇鬱) = 窪淵廠獵鹽選淵構蓋膚蓋膚製簾廠齋網選繭構 (範範齋鏇襯獵憲襯鹽鬱 )	积极	2023-11-04